98885-93-9

Basic information

• Product Name: 5-hydroxy-1,7-bis-(4-hydroxy-3-methoxy-phenyl)-hepta-1,4,6-trien-3-one
• CAS NO: 98885-93-9
• Molecular Weight: 368.386
• Mol File: 98885-93-9.mol
• Article Data: 18

Chemical Properties

• CAS DataBase Reference: 5-hydroxy-1,7-bis-(4-hydroxy-3-methoxy-phenyl)-hepta-1,4,6-trien-3-one(CAS DataBase Reference)
• NIST Chemistry Reference: 5-hydroxy-1,7-bis-(4-hydroxy-3-methoxy-phenyl)-hepta-1,4,6-trien-3-one(98885-93-9)
• EPA Substance Registry System: 5-hydroxy-1,7-bis-(4-hydroxy-3-methoxy-phenyl)-hepta-1,4,6-trien-3-one(98885-93-9)

Safety Data

• Hazardous Substances Data: 98885-93-9(Hazardous Substances Data)

Upstream product

• 121-33-5 vanillin 
• 123-54-6 acetylacetone 
• 704885-44-9 β-D-glucopyranosiduronic acid 4-formyl-2-methoxyphenyl methyl ester triacetate 
• 30802-02-9 feruloyl-CoA 
• 524-14-1 S-(hydrogen malonyl)coenzyme A 
• 23598-07-4 4-formyl-2-methoxyphenyl 2,3,4,6-tetra-O-acetyl-β?D?galactopyranoside 
• 51482-43-0 4-O-(2',3',4',6'-tetra-O-acetyl-β-D-glucopyranosyl)vanillin 
• 76474-56-1 5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)-4,6-heptadiene-3-one 
• 884506-54-1 (3Z,5E)-4-hydroxy-6-(4-hydroxy-3-methoxyphenyl)hexa-3,5-dien-2-one 

Downstream Products

• 36062-05-2 hexahydrocurcumin 
• 36062-04-1 1,7-bis(4-hydroxy-3-methoxyphenyl)-heptane-3,5-dione 
• 36062-07-4 3,5-dihydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)heptane 
• 131068-23-0 hydrazinocurcumin 
• 153127-42-5 cyclocurcumin 
• 814919-70-5 (1E,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,4,6-trien-3-one 
• 98886-39-6 di-O-benzoyl curcumin 
• 98886-38-5 [2-methoxy-4-[(1E,6E)-7-(3-methoxy-4-propanoyloxyphenyl)-3,5-dioxohepta-1,6-dienyl]phenyl] propanoate 
• 1135-24-6 (E)-3-(4-hydroxy-3-methoxyphenyl)acrylic acid 
• 121-33-5 vanillin 
• 52328-98-0 O,O-dimethyl-curcumin 

Relevant articles and documents

Structure-activity relationship studies of 1,7-diheteroarylhepta-1,4,6-trien-3-ones with two different terminal rings in prostate epithelial cell models

To systematically investigate the structure-activity relationships of 1,7-diheteroarylhepta-1,4,6-trien-3-ones in three human prostate cancer cell models and one human prostate non-neoplastic epithelial cell model, thirty five 1,7-diarylhepta-1,4,6-trien-

DNA-binding and in vitro cytotoxic activity of platinum(II) complexes of curcumin and caffeine

Three Pt(II) complexes containing the natural ligands curcumin and caffeine, namely [Pt(curc)(PPh3)2]Cl (1), [PtCl(curc)(DMSO)] (2) (curc = deprotonated curcumin) and trans-[Pt(caffeine)Cl2(DMSO)] (3), were synthesized and

A curcumin-diglutaric acid conjugated prodrug with improved water solubility and antinociceptive properties compared to curcumin

In this work, a curcumin-diglutaric acid (CurDG) prodrug was synthesized by conjugation of curcumin with glutaric acid via an ester linkage. The water solubility, partition coefficient, release characteristics, and antinociceptive activity of CurDG were compared to those of curcumin. The aqueous solubility of CurDG (7.48 μg/mL) is significantly greater than that of curcumin (0.068 μg/mL). A study in human plasma showed that the CurDG completely releases curcumin within 2 h, suggesting the ability of CurDG to serve as a prodrug of curcumin. A hot plate test in mice showed the highest antinociceptive effect dose of curcumin at 200 mg/kg p.o., whereas CurDG showed the same effect at an effective dose of 100 mg/kg p.o., indicating that CurDG significantly enhanced the antinociceptive effect compared to curcumin. The enhanced antinociceptive effect of CurDG may be due to improved water solubility and increased oral bioavailability compared to curcumin.